Civica Rx, a pharmaceutical company providing drugs in shortage, has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications of Civica-owned abbreviated new drug applications.

This partnership has an initial seven-year term. Initially, the Thermo Fisher collaboration will focus on nine medications that have been in short supply or where the drug supply chain is fragile because there are too few manufacturers making these drugs. Civica’s hospital-led drug selection and medical trends advisory committees helped prioritize these medications for Civica’s research and development efforts.

Civica Rx was founded in 2018 by US hospital systems concerned about generic-drug shortages and philanthropic organizations. To date, nearly 50 health systems are Civica members, representing more than 1,200 US hospitals and over 30% of all licensed US hospital beds. Civica currently has 18 medications in production and/or shipped for use in hospitals across the country. Civica Rx is headed by Martin VanTrieste, formerly chief quality officer at Amgen.

Source: Civica Rx